| Name | Borussertib |
| Description | Borussertib is a first-in-class covalent-allosteric inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Aktwt. |
| In vitro | Borussertib exhibits excellent cellular activity in the nanomolar range with superior profile against clinical candidate Akt inhibitors as well as the cytostatic drug doxorubicin. With the EC50 values are 191±90 nM, 48±15 nM, 5±1 nM, 277±90 nM, 373±54 nM, 7770±641 nM in AN3CA (endometrium), T47D (breast), ZR-75-1 (breast), MCF-7 (breast), BT-474 (breast) and KU-19-19 (bladder) cell lines, respectively[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (41.90 mM), Sonication is recommended.
|
| Keywords | Inhibitor | PKB | Akt | Protein kinase B | Borussertib | inhibit |
| Inhibitors Related | Ethyl gallate | Oridonin | Capivasertib | SKLB-163 | Scutellarin | Methyl-Hesperidin | Artemisinin | Honokiol | (E)-Akt inhibitor-IV | 2,3-Butanediol | MK-2206 dihydrochloride | AKT Kinase Inhibitor |
| Related Compound Libraries | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library |
United States
